KROS Keros Therapeutics, Inc. Insider Trading

Director Jean Jacques Bienaime purchases 1,000 KROS shares at $10.61 under pre-arranged 10b5-1 plan adopted 2025-12-05.

Jean Jacques Bienaime, a director, purchased 1,000 shares at $10.61 on 2026-07-15 as part of a 10b5-1 trading plan established on 2025-12-05, meaning this acquisition was scheduled rather than discretionary. At the current price of $10.64, the position remains near the entry point, and stock is -52.8% from its 52-week high of $22.55. Reviewing Bienaime's prior trades at KROS, recent purchases on 2026-06-15 (+8.2% 30-day return) and 2026-05-15 (-4.1% 30-day return) show mixed near-term outcomes; a trade on 2026-04-15 declined -10.3% over 30 days and -9.7% over 90 days. The company is unprofitable (net income $-23.7M in the latest quarter) with a market cap of $210.6M, indicating significant execution risk that should inform assessment of this ongoing accumulation pattern.

Director Jean Jacques Bienaime purchases 1,000 shares of KROS at $10.19; stock down 53.8% from 52-week high, part of pre-arranged 10b5-1 plan.

Jean Jacques Bienaime, a director, executed a purchase of 1,000 shares at $10.19 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, bringing his holdings to 17,592 shares. This is a scheduled transaction, not a discretionary choice. Bienaime's prior trades at KROS have been mixed: a March 2026 buy showed a 30-day gain of 12.0% followed by a 90-day decline of -8.1%, while subsequent purchases in April and May posted negative 30-day returns of -10.3% and -4.1% respectively. The current stock price of $10.41 is -53.8% from the 52-week high of $22.55, reflecting significant downturn; the company is unprofitable with a net loss of $23,708,000.00 and limited quarterly revenue of $32,000.00. The pre-arranged nature of the purchase negates any inference about timing or conviction.

Director Bienaime buys 1,000 (1.0K shares) KROS at $10.58 under 10b5-1 plan; stock -56.0% from 52-week high.

Director Jean Jacques Bienaime purchased 1,000 shares of Keros Therapeutics at $10.58 on 2026-05-15 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, meaning this was a scheduled transaction rather than a discretionary decision. The stock is currently trading at $9.91, -56.0% from its 52-week high of $22.55 and down 15.1% over the last 30 days. At this same ticker, Bienaime's two prior purchases (2026-04-15 and 2026-03-09) showed mixed results, with 30-day returns of -10.3% and +12.0% respectively. The company is unprofitable with a net loss of $-23,708,000.00 in the latest quarter against revenue of $32,000.00, and trades at a P/E of 4.24 on a market cap of $196,137,104.67. Since the transaction is scheduled under a 10b5-1 plan rather than discretionary, this purchase should be evaluated on plan mechanics and holdings context rather than as a signal of insider conviction.

Director Jean-Jacques Bienaime buys 1,000 KROS shares at $11.70, 37% below 52-week high; stock down 38.1% in 90 days.

Bienaime purchased 1,000 shares at $11.70 on 2026-04-15, increasing his holdings to 8,450 shares from 7,450 shares (+13.4% increase in position). The transaction price sits -46.6% from the 52-week high of $21.84, but the stock has declined -38.1% over the past 90 days, suggesting sustained downward momentum. While his prior buy at KROS on 2026-03-09 showed a strong 30-day return of +12.0%, that outcome was followed by continued weakness in the subsequent 90 days. His cross-ticker buying track record shows 8 prior buys averaging +3.6% over 30 days and +1.1% over 90 days with an 80% win rate. Fundamentally, the company is unprofitable (net income of $-7,280,000.00) with a low P/E of 0.68 and market cap of $230,103,610.11. The recurring purchase activity at depressed levels and the stock's ongoing decline context warrant tracking.

Keros Director Bienaime buys 2.0K shares at $11.21; stock down -48.4% from 52-week high, posting loss-making Q.

Director Jean Jacques Bienaime purchased 2,000 shares at $11.21 on 2026-03-09, increasing his holdings to 7,450 shares (a 36.7% increase from 5,450 shares). The purchase occurs in a challenging backdrop: Keros reported a quarterly net loss of $-7,280,000.00 on revenue of $14,124,000.00, and the stock has fallen -48.4% from its 52-week high of $21.84, trading at $11.27 currently. Across his cross-ticker track record, Bienaime's prior 7 open-market buys averaged a 90-day return of +1.1%, though his buy decisions have achieved an 80.00% 90-day win rate, suggesting selective success in timing acquisitions. The purchase represents a material expansion of his position in a biotech name in a valuation trough, amid active losses, warranting investor scrutiny of the company's cash runway and therapeutic progress."

Pontifax Management 4 G.P. (Director) sells entire stake: 4,787,331 shares for $84,975,125.25 at $17.75 on 2025-10-15

Pontifax Management 4 G.P. (2015) Ltd, listed as a Director, executed 4 separate sales totaling 4,787,331 shares for $84,975,125.25 on 2025-10-15, completely liquidating its position in Keros Therapeutics. The blended average price across all transactions was $17.75. This represents a complete exit—the filer held 4,787,331 shares pre-transaction and 0 shares post-transaction, a -100.0% reduction. Such full elimination of a director-level stake is a material governance signal that warrants investor attention to the timing, rationale, and any concurrent company announcements or changes.

ADAR1 Capital exits KROS entirely: 5.39M shares sold for $95.7M at $17.75 (79.3% above current $14.49).

ADAR1 Capital Management, a 10% owner, executed 3 separate sales on 2025-10-15 totaling 5,389,264 shares for $95,659,436.00 at $17.75 per share, reducing holdings from 5,389,264 shares to 0 shares—a complete exit at a price currently trading 22.4% above today's market ($14.49). The sale price of $17.75 sits markedly below the 52-week high of $70.00 but 85.6% above the 52-week low of $9.55. The company remains unprofitable (annual net income: $-30,696,000.00) despite exceptional revenue growth of +2251.0% year-over-year, indicating aggressive top-line expansion without profitability. This full-position liquidation by a significant insider holder warrants examination of the company's operational trajectory and cash burn dynamics given the early-stage biotech profile and deteriorating stock price (-79.3% from 52-week high).

10% owner ADAR1 Capital bought 934,258 shares ($9.5M) in 5 separate trades on 2025-04-09 at $9.40–$10.33, raising stake to 4.39M shares

ADAR1 Capital, a 10% shareholder, executed 5 separate purchases totaling 934,258 shares for $9,464,512.25 at a blended average price of $10.13, expanding its holding by 27.0% to 4,392,737 shares. The timing is notable given KROS trades at $12.18 currently (82.6% below its 52-week high of $70.00) and the stock is down 16.4% over 90 days despite a recent 3.6% 30-day bounce. The company is unprofitable with a $-53.0M net loss in its latest full year and only $388.0K in latest-quarter revenue, though annual revenue growth was reported at +2251.0%. ADAR1's cross-ticker track record shows 100% win rate on prior buys with +9.4% average 90-day returns, but this represents only 3 prior open-market purchases across all tickers—insufficient to establish pattern reliability at KROS specifically.

OrbiMed Advisors sold 250,000 shares at $44.01, reducing stake by 67.7% to 119,522 shares

OrbiMed Advisors, a Director of Keros Therapeutics, completed 2 separate sales totaling 250,000 shares for $11,002,500.00 at $44.01 per share on 2024-08-13, reducing holdings from 369,522 shares to 119,522 shares. This represents a -67.7% reduction in the insider's position. The timing coincides with the stock trading -34.7% from its 52-week high of $70.48 and down -11.8% over the past 30 days. Keros is unprofitable with negative full-year net income and quarterly revenue of $37,000.00, a deeply early-stage biotech profile where such large liquidations warrant attention to insider conviction about near-term prospects.

Director GORDON CARL L sold 250,000 shares at $44.01 for $11.0M, reducing stake by -67.7% to 119.5K shares

Director Carl L. Gordon executed 2 separate sales totaling 250,000 shares for $11,002,500.00 at $44.01 per share on 2024-08-13, divesting 67.7% of his pre-transaction holdings. The sale occurs as the stock trades at $46.04 (current price), -34.7% from its 52-week high of $70.48 and down 11.8% over the past 30 days. Keros Therapeutics reported revenue of $37,000.00 in the latest quarter and net income of -$45,257,000.00 with persistent unprofitability, creating a fundamental backdrop of cash burn and commercial challenges. Gordon's cross-ticker track record shows positive historical timing with 65% win rate on his prior 20 open-market buys (avg 90d return +173.7%), but this metric does not apply to his sale behavior at this ticker and carries no predictive weight for the direction of KROS post-sale.